| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Ramon y Cajal Agüeras, Santiago |
| dc.contributor.author | Sese Faustino, Marta |
| dc.contributor.author | Capdevila Castillo, Clàudia |
| dc.contributor.author | Aasen, Trond |
| dc.contributor.author | Mattos Arruda, Leticia de |
| dc.contributor.author | Diaz-Cano, Salvador J. |
| dc.contributor.author | Hernandez Losa, Javier |
| dc.contributor.author | Castellví Vives, Josep |
| dc.date.accessioned | 2021-10-22T05:54:06Z |
| dc.date.available | 2021-10-22T05:54:06Z |
| dc.date.issued | 2020-02 |
| dc.identifier.citation | Ramón y Cajal S, Sesé M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl). 2020 Feb;98(2):161–177. |
| dc.identifier.issn | 1432-1440 |
| dc.identifier.uri | https://hdl.handle.net/11351/6436 |
| dc.description | Intratumor heterogeneity; Artificial intelligence; Antitumor therapeutics |
| dc.description.abstract | In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through complex genetic, epigenetic, and protein modifications that drive phenotypic selection in response to environmental pressures. Functionally, heterogeneity provides tumors with significant adaptability. This ranges from mutual beneficial cooperation between cells, which nurture features such as growth and metastasis, to the narrow escape and survival of clonal cell populations that have adapted to thrive under specific conditions such as hypoxia or chemotherapy. These dynamic intercellular interplays are guided by a Darwinian selection landscape between clonal tumor cell populations and the tumor microenvironment. Understanding the involved drivers and functional consequences of such tumor heterogeneity is challenging but also promises to provide novel insight needed to confront the problem of therapeutic resistance in tumors. |
| dc.language.iso | eng |
| dc.publisher | Springer |
| dc.relation.ispartofseries | Journal of Molecular Medicine;98(2) |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Càncer - Tractament |
| dc.subject | Generacions alternants |
| dc.subject.mesh | Genetic Heterogeneity |
| dc.subject.mesh | Neoplasms |
| dc.subject.mesh | /therapy |
| dc.title | Clinical implications of intratumor heterogeneity: challenges and opportunities |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.1007/s00109-020-01874-2 |
| dc.subject.decs | heterogeneidad genética |
| dc.subject.decs | neoplasias |
| dc.subject.decs | /terapia |
| dc.relation.publishversion | https://doi.org/10.1007/s00109-020-01874-2 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Ramón Y Cajal S] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Sesé M, Aasen T] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain. [Capdevila C] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA. [De Mattos-Arruda L] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Diaz-Cano SJ] Department of Histopathology, King’s College Hospital and King’s Health Partners, London, UK. [Hernández-Losa J, Castellví J] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain |
| dc.identifier.pmid | 31970428 |
| dc.identifier.wos | 000508697200001 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI14%2F01320 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F02247 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/1PN/2008-2011/RD12%2F0036%2F0057 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F12%2F00363 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR1799 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00772 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/CPII16%2F00042 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |